Novel stem cell therapy shows promising results for Type 1 diabetes
A stem cell-derived potential therapy VX-880 for treating Type 1 diabetes has resulted in a 91% decrease in daily insulin doses in first patient, according to a recent press release.
Vertex Pharmaceuticals Incorporated has shared results of Phase 1/2 of its clinical trial in which after only 90 days of its ongoing investigational study, the patient's insulin needs were reduced from 34 daily units down to 3 daily units.
For more details, check out the full story on the link below:
Novel Stem Cell-Derived Therapy For Type 1 Diabetes Shows Promising Results
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd